Product nameAnti-PPAR gamma antibody - ChIP Grade
See all PPAR gamma primary antibodies
DescriptionRabbit polyclonal to PPAR gamma - ChIP Grade
SpecificityAb45036 detects peroxisome proliferator activated receptor (PPAR) gamma 2. This antibody does not detect PPAR alpha or PPAR delta. This sequence is from P37231-1 (Isoform 2), the sequence is not present in P37231-2 (Isoform 1) or P37231-3 (Isoform 3).
Tested applicationsSuitable for: ChIP, IP, IHC-P, ICC/IF, Functional Studies, WB, EMSA, ELISAmore details
Species reactivityReacts with: Mouse, Cow, Human, Non human primates
Predicted to work with: Dog, Pig
- NIH-3T3 cell lysate
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.05% Sodium azide
Constituents: 0.1% BSA, PBS
Concentration information loading...
PurityImmunogen affinity purified
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Fatty acids
ChIP Related Products
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab45036 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ChIP||Use at an assay dependent concentration. PubMed: 21247904|
|IP||Use at an assay dependent concentration. PubMed: 21247904|
|IHC-P||Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|Functional Studies||Use at an assay dependent concentration. Ab45036 inhibits PPAR gamma 2 DNA binding.|
|WB||1/500. Predicted molecular weight: 57 kDa.Can be blocked with Human PPAR gamma peptide (ab41762).
By Western blot, this antibody detects an ~56 kDa protein representing PPAR gamma 2 from NIH-3T3 cell lysate.
|EMSA||Use at an assay dependent concentration.|
|ELISA||Use at an assay dependent concentration.|
FunctionReceptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.
Tissue specificityHighest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
Involvement in diseaseNote=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
Sequence similaritiesBelongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.
- Information by UniProt
- CIMT1 antibody
- GLM1 antibody
- NR1C3 antibody
Lane 2 : Anti-PPAR gamma antibody - ChIP Grade (ab45036)
Lane 1 : Protein Marker
Lane 2 : Mouse liver tissue lysate at 1 µg
Lane 2 : IRDye® 680RD Donkey anti-Rabbit
Performed under reducing conditions.
Predicted band size: 57 kDa
Exposure time: 2 seconds
ab45036 staining PPAR gamma in 3T3-L1 cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 and blocked with 3% BSA for 30 minutes at room temperature. Samples were incubated with primary antibody (1:200) for 1 hour at room temperature. A Dylight 680-conjugated Goat anti-rabbit IgG polyclonal was used as the secondary antibody (1/1000).
All lanes : Anti-PPAR gamma antibody - ChIP Grade (ab45036) at 1/500 dilution
Lane 1 : 3T3
Lane 2 : 3T3-L1 differentiated day 7
Lysates/proteins at 20 µg per lane.
Predicted band size: 57 kDa
PPAR gamma is detected in 3T3-L1 Day 7 differentiated cell lysates with some background bands. No detection of PPAR gamma occurs in 3T3 cell lysate.
ab45036 positive staining PPAR gamma in Hela cells by ICC/IF (Immunocytochemistry/immunofluorescence) (right) negative control in abscence of ab45036 (left). Cells were fixed with formalin, permeabilized with 0.1% Triton X-100 and blocked with 3% BSA for 30 minutes at room temperature. Samples were incubated with primary antibody (1/200 in PBS + 3% BSA) over night at 4°C. A DyLight 488-conjugated Goat anti-rabbit IgG polyclonal was used as the secondary antibody. F-actin (red) stained with red phalloidin and nuclei (blue) stainded with DAPI.
Immunocytochemical analysis of PPAR gamma using ab45036 at the dilution 1/200. The image at the top shows 3T3-L1 cells differntiated (for 7 days) where PPAR gamma is shown in green. The image below shows 3T3-L1 undifferentiated cells where no PPAR gamma is detected.
Immunocytochemical analysis of PPAR gamma using ab45036 at the dilution 1/200. 3T3-L1 cells providing positive signal have been differentiated for 7 days.
PPAR gamma is shown in red, lipid droplets (that indicates the proper differentiation of the cells) are shown in green.
This product has been referenced in:
- Zheng F & Cai Y Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-? and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet. Lipids Health Dis 18:6 (2019). Read more (PubMed: 30611282) »
- Desmarais F et al. Apolipoprotein D overexpression alters hepatic prostaglandin and omega fatty acid metabolism during the development of a non-inflammatory hepatic steatosis. Biochim Biophys Acta Mol Cell Biol Lipids 1864:522-531 (2019). Read more (PubMed: 30630053) »